- IBDEI3IP ; ; 19-NOV-2015
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
- Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.4,1817,0)
- ;;=NEW PATIENT^2^165
- ;;^UTILITY(U,$J,358.4,1818,0)
- ;;=ESTABLISHED PATIENT^1^165
- ;;^UTILITY(U,$J,358.4,1819,0)
- ;;=CONSULTATIONS^3^165
- ;;^UTILITY(U,$J,358.4,1820,0)
- ;;=PREGNANCY COMPLICATIONS^9^166
- ;;^UTILITY(U,$J,358.4,1821,0)
- ;;=PREGNANCY-HYPERTENSION^12^166
- ;;^UTILITY(U,$J,358.4,1822,0)
- ;;=PREGNANCY-VOMITING^15^166
- ;;^UTILITY(U,$J,358.4,1823,0)
- ;;=LATE PREGNANCY^6^166
- ;;^UTILITY(U,$J,358.4,1824,0)
- ;;=PREGNANCY-OTH COMPLICATIONS^13^166
- ;;^UTILITY(U,$J,358.4,1825,0)
- ;;=PREGNANCY CONDITIONS^10^166
- ;;^UTILITY(U,$J,358.4,1826,0)
- ;;=MULTIPLE GESTATIONS^8^166
- ;;^UTILITY(U,$J,358.4,1827,0)
- ;;=PREGNANCY-FETAL ABNORMALITY^11^166
- ;;^UTILITY(U,$J,358.4,1828,0)
- ;;=AMNIO/MEMBRANE PROBLEMS^1^166
- ;;^UTILITY(U,$J,358.4,1829,0)
- ;;=MAJOR PUERPERAL INFECTIONS^7^166
- ;;^UTILITY(U,$J,358.4,1830,0)
- ;;=VENOUS COMPLICATIONS^18^166
- ;;^UTILITY(U,$J,358.4,1831,0)
- ;;=PREGNANCY-PYREXIA^14^166
- ;;^UTILITY(U,$J,358.4,1832,0)
- ;;=PUERPERIUM COMPLICATIONS^17^166
- ;;^UTILITY(U,$J,358.4,1833,0)
- ;;=INFECTIONS BREAST/NIPPLE^5^166
- ;;^UTILITY(U,$J,358.4,1834,0)
- ;;=PREGNANCY-Z CODES^16^166
- ;;^UTILITY(U,$J,358.4,1835,0)
- ;;=GYNECOLOGICAL/BREAST^4^166
- ;;^UTILITY(U,$J,358.4,1836,0)
- ;;=GENITOURINARY & RENAL^3^166
- ;;^UTILITY(U,$J,358.4,1837,0)
- ;;=GASTROINTESTINAL^2^166
- ;;^UTILITY(U,$J,358.4,1838,0)
- ;;=SPECIAL SERVICES^9^167
- ;;^UTILITY(U,$J,358.4,1839,0)
- ;;=CHEMO NURSE PROCEDURES^2^167
- ;;^UTILITY(U,$J,358.4,1840,0)
- ;;=INFUSION DRUGS^6^167
- ;;^UTILITY(U,$J,358.4,1841,0)
- ;;=BLOOD PRODUCTS^1^167
- ;;^UTILITY(U,$J,358.4,1842,0)
- ;;=DIAGNOSTIC PROCEDURES^3^167
- ;;^UTILITY(U,$J,358.4,1843,0)
- ;;=OTHER DRUGS^7^167
- ;;^UTILITY(U,$J,358.4,1844,0)
- ;;=IMMUNIZATION ADMINISTRATION^4^167
- ;;^UTILITY(U,$J,358.4,1845,0)
- ;;=IMMUNIZATIONS^5^167
- ;;^UTILITY(U,$J,358.4,1846,0)
- ;;=PROLONGED SERVICES^8^167
- ;;^UTILITY(U,$J,358.4,1847,0)
- ;;=NEW PATIENT^2^168
- ;;^UTILITY(U,$J,358.4,1848,0)
- ;;=ESTABLISHED PATIENT^1^168
- ;;^UTILITY(U,$J,358.4,1849,0)
- ;;=CONSULTATIONS^3^168
- ;;^UTILITY(U,$J,358.4,1850,0)
- ;;=ANEMIA^1^169
- ;;^UTILITY(U,$J,358.4,1851,0)
- ;;=ARTIFICIAL OPENING STATUS^2^169
- ;;^UTILITY(U,$J,358.4,1852,0)
- ;;=BREASTS and GYN NEOPLASMS^3^169
- ;;^UTILITY(U,$J,358.4,1853,0)
- ;;=COAGULATION DISORDERS^4^169
- ;;^UTILITY(U,$J,358.4,1854,0)
- ;;=COUNSELING AND SCREENING^5^169
- ;;^UTILITY(U,$J,358.4,1855,0)
- ;;=GENITOURINARY NEOPLASMS^6^169
- ;;^UTILITY(U,$J,358.4,1856,0)
- ;;=GI CANCER^7^169
- ;;^UTILITY(U,$J,358.4,1857,0)
- ;;=HEAD NECK AND LUNGS NEOPLASMS^8^169
- ;;^UTILITY(U,$J,358.4,1858,0)
- ;;=HEMOGLOBINOPATHIES^9^169
- ;;^UTILITY(U,$J,358.4,1859,0)
- ;;=LYMPHOID NEOPLASMS^10^169
- ;;^UTILITY(U,$J,358.4,1860,0)
- ;;=METASTATIC SITES^11^169
- ;;^UTILITY(U,$J,358.4,1861,0)
- ;;=MALIGNANT NEOPLASMS OF OTHER SITES^12^169
- ;;^UTILITY(U,$J,358.4,1862,0)
- ;;=MYELOID NEOPLASMS AND DISORDERS^13^169
- ;;^UTILITY(U,$J,358.4,1863,0)
- ;;=NEOPLASM OF UNCERTAIN BEHAVIOR^14^169
- ;;^UTILITY(U,$J,358.4,1864,0)
- ;;=NEOPLASM OF UNSPECIFIED NATURE^15^169
- ;;^UTILITY(U,$J,358.4,1865,0)
- ;;=PERSONAL HISTORY^16^169
- ;;^UTILITY(U,$J,358.4,1866,0)
- ;;=INJECTION/ASPIRATION^3^170
- ;;^UTILITY(U,$J,358.4,1867,0)
- ;;=FRACTURE DISLOCATION^2^170
- ;;^UTILITY(U,$J,358.4,1868,0)
- ;;=APPLICATION CASTS/STRAPPING^1^170
- ;;^UTILITY(U,$J,358.4,1869,0)
- ;;=OTHER/REMOVAL/REVISION^4^170
- ;;^UTILITY(U,$J,358.4,1870,0)
- ;;=SUPPLIES/SOFT GOODS^7^170
- ;;^UTILITY(U,$J,358.4,1871,0)
- ;;=SUPPLIES/DRUGS^6^170
- ;;^UTILITY(U,$J,358.4,1872,0)
- ;;=REPAIR/CLOSURE-SIMPLE^5^170
- ;;^UTILITY(U,$J,358.4,1873,0)
- ;;=NEW PATIENT^2^171
- ;;^UTILITY(U,$J,358.4,1874,0)
- ;;=ESTABLISHED PATIENT^1^171
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3IP 3971 printed Feb 19, 2025@00:15:58 Page 2
- IBDEI3IP ; ; 19-NOV-2015
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
- +2 if 'DIFQR(358.4)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.4,1817,0)
- +2 ;;=NEW PATIENT^2^165
- +3 ;;^UTILITY(U,$J,358.4,1818,0)
- +4 ;;=ESTABLISHED PATIENT^1^165
- +5 ;;^UTILITY(U,$J,358.4,1819,0)
- +6 ;;=CONSULTATIONS^3^165
- +7 ;;^UTILITY(U,$J,358.4,1820,0)
- +8 ;;=PREGNANCY COMPLICATIONS^9^166
- +9 ;;^UTILITY(U,$J,358.4,1821,0)
- +10 ;;=PREGNANCY-HYPERTENSION^12^166
- +11 ;;^UTILITY(U,$J,358.4,1822,0)
- +12 ;;=PREGNANCY-VOMITING^15^166
- +13 ;;^UTILITY(U,$J,358.4,1823,0)
- +14 ;;=LATE PREGNANCY^6^166
- +15 ;;^UTILITY(U,$J,358.4,1824,0)
- +16 ;;=PREGNANCY-OTH COMPLICATIONS^13^166
- +17 ;;^UTILITY(U,$J,358.4,1825,0)
- +18 ;;=PREGNANCY CONDITIONS^10^166
- +19 ;;^UTILITY(U,$J,358.4,1826,0)
- +20 ;;=MULTIPLE GESTATIONS^8^166
- +21 ;;^UTILITY(U,$J,358.4,1827,0)
- +22 ;;=PREGNANCY-FETAL ABNORMALITY^11^166
- +23 ;;^UTILITY(U,$J,358.4,1828,0)
- +24 ;;=AMNIO/MEMBRANE PROBLEMS^1^166
- +25 ;;^UTILITY(U,$J,358.4,1829,0)
- +26 ;;=MAJOR PUERPERAL INFECTIONS^7^166
- +27 ;;^UTILITY(U,$J,358.4,1830,0)
- +28 ;;=VENOUS COMPLICATIONS^18^166
- +29 ;;^UTILITY(U,$J,358.4,1831,0)
- +30 ;;=PREGNANCY-PYREXIA^14^166
- +31 ;;^UTILITY(U,$J,358.4,1832,0)
- +32 ;;=PUERPERIUM COMPLICATIONS^17^166
- +33 ;;^UTILITY(U,$J,358.4,1833,0)
- +34 ;;=INFECTIONS BREAST/NIPPLE^5^166
- +35 ;;^UTILITY(U,$J,358.4,1834,0)
- +36 ;;=PREGNANCY-Z CODES^16^166
- +37 ;;^UTILITY(U,$J,358.4,1835,0)
- +38 ;;=GYNECOLOGICAL/BREAST^4^166
- +39 ;;^UTILITY(U,$J,358.4,1836,0)
- +40 ;;=GENITOURINARY & RENAL^3^166
- +41 ;;^UTILITY(U,$J,358.4,1837,0)
- +42 ;;=GASTROINTESTINAL^2^166
- +43 ;;^UTILITY(U,$J,358.4,1838,0)
- +44 ;;=SPECIAL SERVICES^9^167
- +45 ;;^UTILITY(U,$J,358.4,1839,0)
- +46 ;;=CHEMO NURSE PROCEDURES^2^167
- +47 ;;^UTILITY(U,$J,358.4,1840,0)
- +48 ;;=INFUSION DRUGS^6^167
- +49 ;;^UTILITY(U,$J,358.4,1841,0)
- +50 ;;=BLOOD PRODUCTS^1^167
- +51 ;;^UTILITY(U,$J,358.4,1842,0)
- +52 ;;=DIAGNOSTIC PROCEDURES^3^167
- +53 ;;^UTILITY(U,$J,358.4,1843,0)
- +54 ;;=OTHER DRUGS^7^167
- +55 ;;^UTILITY(U,$J,358.4,1844,0)
- +56 ;;=IMMUNIZATION ADMINISTRATION^4^167
- +57 ;;^UTILITY(U,$J,358.4,1845,0)
- +58 ;;=IMMUNIZATIONS^5^167
- +59 ;;^UTILITY(U,$J,358.4,1846,0)
- +60 ;;=PROLONGED SERVICES^8^167
- +61 ;;^UTILITY(U,$J,358.4,1847,0)
- +62 ;;=NEW PATIENT^2^168
- +63 ;;^UTILITY(U,$J,358.4,1848,0)
- +64 ;;=ESTABLISHED PATIENT^1^168
- +65 ;;^UTILITY(U,$J,358.4,1849,0)
- +66 ;;=CONSULTATIONS^3^168
- +67 ;;^UTILITY(U,$J,358.4,1850,0)
- +68 ;;=ANEMIA^1^169
- +69 ;;^UTILITY(U,$J,358.4,1851,0)
- +70 ;;=ARTIFICIAL OPENING STATUS^2^169
- +71 ;;^UTILITY(U,$J,358.4,1852,0)
- +72 ;;=BREASTS and GYN NEOPLASMS^3^169
- +73 ;;^UTILITY(U,$J,358.4,1853,0)
- +74 ;;=COAGULATION DISORDERS^4^169
- +75 ;;^UTILITY(U,$J,358.4,1854,0)
- +76 ;;=COUNSELING AND SCREENING^5^169
- +77 ;;^UTILITY(U,$J,358.4,1855,0)
- +78 ;;=GENITOURINARY NEOPLASMS^6^169
- +79 ;;^UTILITY(U,$J,358.4,1856,0)
- +80 ;;=GI CANCER^7^169
- +81 ;;^UTILITY(U,$J,358.4,1857,0)
- +82 ;;=HEAD NECK AND LUNGS NEOPLASMS^8^169
- +83 ;;^UTILITY(U,$J,358.4,1858,0)
- +84 ;;=HEMOGLOBINOPATHIES^9^169
- +85 ;;^UTILITY(U,$J,358.4,1859,0)
- +86 ;;=LYMPHOID NEOPLASMS^10^169
- +87 ;;^UTILITY(U,$J,358.4,1860,0)
- +88 ;;=METASTATIC SITES^11^169
- +89 ;;^UTILITY(U,$J,358.4,1861,0)
- +90 ;;=MALIGNANT NEOPLASMS OF OTHER SITES^12^169
- +91 ;;^UTILITY(U,$J,358.4,1862,0)
- +92 ;;=MYELOID NEOPLASMS AND DISORDERS^13^169
- +93 ;;^UTILITY(U,$J,358.4,1863,0)
- +94 ;;=NEOPLASM OF UNCERTAIN BEHAVIOR^14^169
- +95 ;;^UTILITY(U,$J,358.4,1864,0)
- +96 ;;=NEOPLASM OF UNSPECIFIED NATURE^15^169
- +97 ;;^UTILITY(U,$J,358.4,1865,0)
- +98 ;;=PERSONAL HISTORY^16^169
- +99 ;;^UTILITY(U,$J,358.4,1866,0)
- +100 ;;=INJECTION/ASPIRATION^3^170
- +101 ;;^UTILITY(U,$J,358.4,1867,0)
- +102 ;;=FRACTURE DISLOCATION^2^170
- +103 ;;^UTILITY(U,$J,358.4,1868,0)
- +104 ;;=APPLICATION CASTS/STRAPPING^1^170
- +105 ;;^UTILITY(U,$J,358.4,1869,0)
- +106 ;;=OTHER/REMOVAL/REVISION^4^170
- +107 ;;^UTILITY(U,$J,358.4,1870,0)
- +108 ;;=SUPPLIES/SOFT GOODS^7^170
- +109 ;;^UTILITY(U,$J,358.4,1871,0)
- +110 ;;=SUPPLIES/DRUGS^6^170
- +111 ;;^UTILITY(U,$J,358.4,1872,0)
- +112 ;;=REPAIR/CLOSURE-SIMPLE^5^170
- +113 ;;^UTILITY(U,$J,358.4,1873,0)
- +114 ;;=NEW PATIENT^2^171
- +115 ;;^UTILITY(U,$J,358.4,1874,0)
- +116 ;;=ESTABLISHED PATIENT^1^171
